Liraglutide
A plain-English guide to the once-daily GLP-1 medicine that helped establish the modern incretin era—covering how it works, what major human trials found, and where it differs from newer weekly agents.
Why it still matters
Liraglutide brought long-acting GLP-1 receptor activation into once-daily treatment and later produced major evidence in weight management and cardiovascular outcomes.
What is liraglutide?
Liraglutide is a laboratory-made analogue of human GLP-1, a gut hormone involved in glucose regulation, appetite, and digestion.
Single receptor
It activates the GLP-1 receptor. Unlike tirzepatide or retatrutide, it is not a multi-receptor agonist.
Daily profile
Fatty-acid modification and albumin binding extend activity enough for once-daily administration.
Appetite effects
Human studies associate liraglutide with lower energy intake, greater fullness, and clinically meaningful weight loss.
Mature evidence
Its evidence base includes large randomized trials in type 2 diabetes, obesity, and cardiovascular risk.
From short-lived hormone to daily medicine
How GLP-1 receptor activation changes the metabolic conversation
Liraglutide does not simply “burn fat.” Its effects emerge from several connected signals.
Pancreas
When glucose is elevated, GLP-1 receptor signaling increases insulin release and reduces inappropriate glucagon signaling. The effect is glucose-dependent.
Brain and appetite
Central appetite pathways receive stronger satiety signals, which can reduce hunger and energy intake.
Stomach
Gastric emptying can slow, especially early in treatment. This contributes to fullness but also helps explain common gastrointestinal effects.
Two trials that define the liraglutide story
These results apply to the specific participants, protocols, and regulated product used in each trial—not to unverified research material.
56 weeks in adults without diabetes
3,731 adults with obesity, or overweight plus a qualifying condition, were randomized to liraglutide 3.0 mg or placebo alongside lifestyle counseling.
63.2% versus 27.1% lost at least 5% of baseline weight. Nausea and diarrhea were the most frequently reported adverse effects.
3.8-year median follow-up in high-risk type 2 diabetes
9,340 adults were randomized to liraglutide or placebo in addition to standard care.
The primary outcome combined cardiovascular death, nonfatal heart attack, or nonfatal stroke. The population was specifically people with type 2 diabetes and high cardiovascular risk.
Where liraglutide fits among roadmap peptides
| Compound | Primary signaling | Typical approved/research interval | Key distinction |
|---|---|---|---|
| Liraglutide | GLP-1 | Daily | Mature outcomes evidence; shorter acting than newer agents. |
| Semaglutide | GLP-1 | Weekly for injectable products | Longer acting GLP-1 analogue. |
| Tirzepatide | GIP + GLP-1 | Weekly | Dual incretin receptor agonist. |
| Retatrutide | GIP + GLP-1 + glucagon | Weekly in trials | Investigational triple agonist. |
| Cagrilintide | Amylin pathway | Weekly in trials | Not a GLP-1 agonist; studied alone and in combinations. |
Published human research vs community formats
The distinction matters: clinical-trial amounts are evidence; community vial practices are not.
Published and approved-product research
- Type 2 diabetes studies commonly evaluated once-daily amounts up to 1.8 mg.
- Weight-management studies evaluated a once-daily target of 3.0 mg, reached through staged escalation.
- Regulated U.S. pens contain a ready-to-use 6 mg/mL solution.
Community research formats
- Lyophilized vials may be discussed in 5 mg or 10 mg formats.
- These formats are not the FDA-approved presentation and may vary in identity, purity, and concentration.
- Community observations are not a substitute for controlled human evidence or professional care.
Hypothetical reconstitution and U-100 syringe math
This is concentration arithmetic—not a preparation protocol, dosing recommendation, or instruction for use.
A smaller research-market format. It is not an FDA-approved liraglutide presentation, and its quality cannot be inferred from clinical trials.
This is the hypothetical vial used in the concentration example because 10 mg with 2 mL produces simple, auditable U-100 syringe math.
The regulated presentation is already a clear solution. It is included as the clinical reference point and must not be reconstituted.
hypothetical vial
hypothetical diluent
concentration
| U-100 units | Liquid volume | Equivalent amount at 5 mg/mL | Reference point |
|---|---|---|---|
| 6 units | 0.06 mL | 0.30 mg | Math reference only |
| 12 units | 0.12 mL | 0.60 mg | Published escalation reference |
| 24 units | 0.24 mL | 1.20 mg | Published clinical reference |
| 36 units | 0.36 mL | 1.80 mg | Published diabetes-study reference |
| 48 units | 0.48 mL | 2.40 mg | Published escalation reference |
| 60 units | 0.60 mL | 3.00 mg | Published weight-management target |
Formula: amount (mg) ÷ concentration (mg/mL) = volume (mL). On a U-100 syringe, 1 mL equals 100 units. Verify all arithmetic independently. Learn the concepts in What Is Reconstitution? and the U-100 Syringe Guide.
Storage depends on the presentation
Approved unopened pens
Follow the current product label. U.S. labeling specifies refrigeration at 2°C to 8°C (36°F to 46°F) before first use. Do not freeze.
Approved pens in use
Current U.S. labeling permits storage for 30 days at 15°C to 30°C (59°F to 86°F) or refrigerated at 2°C to 8°C. Protect from excessive heat and sunlight.
Research material
Stability cannot be assumed from an approved pen label. Follow validated laboratory documentation for the exact material and avoid repeated temperature swings, contamination, and vigorous handling.
Important safety signals are not optional context
Liraglutide is a prescription medicine with meaningful contraindications, warnings, and interaction considerations.
Commonly reported effects
- Nausea, diarrhea, constipation, vomiting, and abdominal discomfort
- Reduced appetite
- Headache, fatigue, or dizziness in some studies
- Injection-site reactions
Serious warnings and precautions
- Boxed warning concerning thyroid C-cell tumors observed in rodents; human relevance is uncertain
- Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2
- Acute pancreatitis, gallbladder disease, dehydration-related kidney injury, and increased heart rate
- Hypoglycemia risk rises when combined with insulin or insulin secretagogues
- Severe gastrointestinal reactions and aspiration risk around anesthesia or deep sedation require clinical attention
Common questions about liraglutide
Is liraglutide the same as semaglutide?
No. Both activate the GLP-1 receptor, but they are different molecules with different pharmacokinetics. Liraglutide is generally once daily; injectable semaglutide products are generally once weekly. See the roadmap-listed Semaglutide page.
Is liraglutide a peptide?
Yes. It is an acylated peptide analogue with 97% amino-acid sequence similarity to native human GLP-1.
Why is liraglutide taken daily?
Its molecular modifications extend its action far beyond native GLP-1, but its approximately 13-hour half-life is still shorter than that of newer weekly GLP-1 analogues.
Does liraglutide need to be reconstituted?
Approved Victoza and Saxenda pens do not. They are supplied as ready-to-use 6 mg/mL solutions. Lyophilized research formats are different, non-approved presentations.
What is the difference between Victoza and Saxenda?
Both contain liraglutide. In the U.S., their labeled indications, maximum amounts, and pen dose selections differ: Victoza is used for type 2 diabetes and certain cardiovascular-risk reduction indications, while Saxenda is labeled for chronic weight management in qualifying populations.
Does liraglutide have human cardiovascular evidence?
Yes. In LEADER, among people with type 2 diabetes and high cardiovascular risk, the primary cardiovascular outcome occurred less often with liraglutide than placebo. That finding should not be generalized to every population.
Can research-vial results be assumed to match clinical trials?
No. Major trials used regulated products with verified identity, concentration, and manufacturing controls. Unverified materials cannot be assumed equivalent.
Roadmap-listed resources
Every link below uses an exact URL from the TalkingPeps Knowledge Library roadmap.
Primary sources
Titles and identifiers are shown as plain text so that all clickable links on this page remain restricted to roadmap URLs.
- U.S. Food and Drug Administration. Saxenda (liraglutide) injection, Prescribing Information. 2025. Application 206321.
- U.S. Food and Drug Administration. Victoza (liraglutide) injection, Prescribing Information. 2025. Application 022341.
- Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015;373:11-22. DOI: 10.1056/NEJMoa1411892.
- Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375:311-322. DOI: 10.1056/NEJMoa1603827.
Good research starts with good questions.
Use the library to compare evidence, understand measurements, and separate established findings from online claims.
Explore the Research Library